{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:35:20Z","timestamp":1786980920016,"version":"build-2736575974"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T00:00:00Z","timestamp":1522972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T00:00:00Z","timestamp":1522972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1007\/s10637-018-0596-7","type":"journal-article","created":{"date-parts":[[2018,4,6]],"date-time":"2018-04-06T16:30:36Z","timestamp":1523032236000},"page":"726-731","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Nivolumab-induced acute granulomatous tubulointerstitial nephritis in a patient with gastric cancer"],"prefix":"10.1007","volume":"36","author":[{"given":"Yoshihisa","family":"Nakatani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3280-4850","authenticated-orcid":false,"given":"Hisato","family":"Kawakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiyo","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Mashiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasutoshi","family":"Takashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,4,6]]},"reference":[{"key":"596_CR1","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, Yeh KH, Yoshikawa T, Oh SC, Bai LY, Tamura T, Lee KW, Hamamoto Y, Kim JG, Chin K, Oh DY, Minashi K, Cho JY, Tsuda M, Chen LT (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461\u20132471","journal-title":"Lancet"},{"key":"596_CR2","unstructured":"Opdivo (Nivolumab). https:\/\/packageinserts.bms.com\/pi\/pi_opdivo.pdf. Accessed 1 Mar 2018"},{"key":"596_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","volume":"373","author":"RJ Motzer","year":"2015","unstructured":"Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK, Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P (2015) Nivolumab versus Everolimus in advanced renal-cell carcinoma. N Engl J Med 373:1803\u20131813","journal-title":"N Engl J Med"},{"key":"596_CR4","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","volume":"373","author":"H Borghaei","year":"2015","unstructured":"Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, Barlesi F, Kohlh\u00e4ufl M, Arrieta O, Burgio MA, Fayette J, Lena H, Poddubskaya E, Gerber DE, Gettinger SN, Rudin CM, Rizvi N, Crin\u00f2 L, Blumenschein GR Jr, Antonia SJ, Dorange C, Harbison CT, Graf Finckenstein F, Brahmer JR (2015) Nivolumab versus docetaxel in advanced Nonsquamous non-small-cell lung Cancer. N Engl J Med 373:1627\u20131639","journal-title":"N Engl J Med"},{"key":"596_CR5","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1200\/JCO.2018.36.15_suppl.6085","volume":"36","author":"I Chau","year":"2018","unstructured":"Chau I, Chen LT, Kang YK et al (2018) Nivolumab safety profile in Asian and western patients with chemotherapy-refractory (CTx-R) advanced gastric\/gastroesophageal junction (adv G\/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials. J Clin Oncol 36:2018 (suppl 4S; abstr 90)","journal-title":"J Clin Oncol"},{"key":"596_CR6","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1038\/bjc.2016.358","volume":"115","author":"J Belliere","year":"2016","unstructured":"Belliere J, Meyer N, Mazieres J, Ollier S, Boulinguez S, Delas A, Ribes D, Faguer S (2016) Acute interstitial nephritis related to immune checkpoint inhibitors. Br J Cancer 115:1457\u20131461","journal-title":"Br J Cancer"},{"key":"596_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40425-016-0205-2","volume":"5","author":"J Escandon","year":"2017","unstructured":"Escandon J, Peacock S, Trabolsi A, Thomas DB, Layka A, Lutzky J (2017) Interstitial nephritis in melanoma patients secondary to PD-1 checkpoint inhibitor. J Immunother Cancer 5:3","journal-title":"J Immunother Cancer"},{"key":"596_CR8","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/ndt\/gfw467","volume":"32","author":"H Izzedine","year":"2017","unstructured":"Izzedine H, Mateus C, Boutros C et al (2017) Renal effects of immune checkpoint inhibitors. Nephrol Dial Transplant 32:936\u2013942","journal-title":"Nephrol Dial Transplant"},{"key":"596_CR9","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1159\/000089686","volume":"102","author":"Y Chen","year":"2006","unstructured":"Chen Y, Zhang J, Li J, Zou L, Zhao T, Tang Y, Wu Y (2006) Expression of B7-H1 in inflammatory renal tubular epithelial cells. Nephron Exp Nephrol 102:e81\u2013e92","journal-title":"Nephron Exp Nephrol"},{"key":"596_CR10","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1038\/ki.1990.46","volume":"37","author":"RP Wuthrich","year":"1990","unstructured":"Wuthrich RP, Glimcher LH, Yui MA, Jevnikar AM, Dumas SE, Kelley VE (1990) MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells. Kidney Int 37:783\u2013792","journal-title":"Kidney Int"},{"key":"596_CR11","doi-asserted-by":"publisher","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","volume":"28","author":"JR Brahmer","year":"2010","unstructured":"Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, Gilson MM, Wang C, Selby M, Taube JM, Anders R, Chen L, Korman AJ, Pardoll DM, Lowy I, Topalian SL (2010) Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 28:3167\u20133175","journal-title":"J Clin Oncol"},{"key":"596_CR12","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1159\/000455014","volume":"45","author":"R Wanchoo","year":"2017","unstructured":"Wanchoo R, Karam S, Uppal NN, Barta VS, Deray G, Devoe C, Launay-Vacher V, Jhaveri KD, on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) Adverse renal effects of immune checkpoint inhibitors: a narrative review. Am J Nephrol 45:160\u2013169","journal-title":"Am J Nephrol"},{"key":"596_CR13","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","volume":"4","author":"K Haratani","year":"2018","unstructured":"Haratani K, Hayashi H, Chiba Y, Kudo K, Yonesaka K, Kato R, Kaneda H, Hasegawa Y, Tanaka K, Takeda M, Nakagawa K (2018) Association of Immune-Related Adverse Events with Nivolumab Efficacy in non-small-cell lung Cancer. JAMA Oncol 4:374\u2013378","journal-title":"JAMA Oncol"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0596-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0596-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0596-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T13:23:15Z","timestamp":1678540995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0596-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,6]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["596"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0596-7","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,4,6]]},"assertion":[{"value":"9 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Yoshihisa Nakatani declares that he has no conflict of interest. Hisato Kawakami has received honoraria from Ono Pharmaceutical Co. Ltd. Masashi Ichikawa declares that he has no conflict of interest. Sachiyo Yamamoto declares that she has no conflict of interest. Yasuo Otsuka declares that he has no conflict of interest. Akiko Mashiko declares that she has no conflict of interest. Yasutoshi Takashima declares that he has no conflict of interest. Akihiko Ito declares that he has no conflict of interest. Kazuhiko Nakagawa has received honoraria and research funding from Ono Pharmaceutical Co. Ltd. and Bristol Myers Squibb Co. as well as consulting fees from Ono Pharmaceutical Co. Ltd. Shuji Arima declares that he has no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}